Borgström L, Johansson C G, Larsson H, Lenander R
J Pharmacokinet Biopharm. 1981 Aug;9(4):431-41. doi: 10.1007/BF01060887.
The pharmacokinetics of bendroflumethiazide after oral administration of 1.25, 2.5, and 5.0 mg were studied in nine healthy male volunteers. Bendroflumethiazide was analyzed by GLC after extractive alkylation. After the lowest dose, the plasma concentration, could be followed to 14 hr, and the data were adequately fitted by a one-compartment model; the half-life was 3.1 hr. After the 2.5 and 5.0 mg doses, the plasma concentration was followed for 24 hr, and the data were fitted by a two-compartment model with half-lives of 8.9 hr. The urinary sodium concentration was doubled after bendroflumethiazide intake, but the urinary potassium concentration remained almost constant. The renal clearance of bendroflumethiazide was around 30 ml . min-1.
在9名健康男性志愿者中研究了口服1.25毫克、2.5毫克和5.0毫克苄氟噻嗪后的药代动力学。经萃取烷基化后，用气相色谱法分析苄氟噻嗪。给予最低剂量后，血浆浓度可追踪至14小时，数据用单室模型拟合良好；半衰期为3.1小时。给予2.5毫克和5.0毫克剂量后，血浆浓度追踪24小时，数据用双室模型拟合，半衰期为8.9小时。摄入苄氟噻嗪后尿钠浓度加倍，但尿钾浓度几乎保持不变。苄氟噻嗪的肾清除率约为30毫升·分钟-1。
